I BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Viiv Healthcare B.V. submitted in 2024 an application for Triumeq 5 mg/60 mg/30 mg dispersible tablets[1] (HA791) to be assessed with the aim of including Triumeq in the list of prequalified medicinal products for the management of HIV/AIDS.

Triumeq was assessed according to the 'Procedure for Assessing the Acceptability, in principle, of Pharmaceutical Products for purchase by United Nations Agencies' by the team of WHO assessors. The assessors are senior experts, mainly from National Authorities, invited by WHO to participate in the prequalification assessment process.

2. Steps taken in the evaluation of the product

February 2024	The quality data were reviewed and found to comply with the relevant WHO requirements.
05 March 2024	Triumeq 5 mg/60 mg/30 mg dispersible tablets was included in the list of prequalified medicinal products.

II GENERAL CONDITIONS FOR THE PREQUALIFICATION

Further information is available at:

https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products

https://www.ema.europa.eu/en/medicines/human/EPAR/triumeq
EMEA/H/C/002754

[1] Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority's responsibility Throughout this WHOPAR the proprietary name is given as an example only